West Pharmaceutical Services (WST) Gross Margin (2009 - 2026)

West Pharmaceutical Services has disclosed Gross Margin across 18 years of filings, most recently posting 35.08% for Q1 2026.

• Gross Margin for Q1 2026 came in at 35.08%, up 186.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 36.28% (up 174.0% YoY), and the FY2025 annual result was 35.91%, up 140.0% from the prior year.
• Gross Margin came in at 35.08% for Q1 2026 at West Pharmaceutical Services, down from 37.75% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 41.68% in Q2 2022 to a low of 32.76% in Q2 2024.
• The 5-year median for Gross Margin is 36.98% (2022), against an average of 36.85%.
• Across the five-year window, Gross Margin sank 590 bps in 2024 and jumped 297 bps in 2025, its largest moves.
• West Pharmaceutical Services' Gross Margin stood at 36.98% in 2022, then grew by 3 bps to 38.01% in 2023, then declined by 4 bps to 36.54% in 2024, then advanced by 3 bps to 37.75% in 2025, then retreated by 7 bps to 35.08% in 2026.
• The last three Gross Margin figures came in at 35.08% (Q1 2026), 37.75% (Q4 2025), and 36.58% (Q3 2025), per Business Quant data.